Piper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $44
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst David Amsellem maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $42 to $44.
Piper Sandler analyst David Amsellem maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $42 to $44.